These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 7941876)

  • 1. [The dependence of the antigen-binding activity of immunoglobulin preparations on their molecular composition].
    Migunov VN; Pozina IM; Levina LA; Chulok TA; Severtseva MK; Minakova LV; Temper RM; Klimova ZV
    Zh Mikrobiol Epidemiol Immunobiol; 1994; (3):88-92. PubMed ID: 7941876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Class-M and -G antipolysaccharide antibodies in human immunoglobulin preparations].
    Chulok TA; Zaĭtseva EV; Klimova ZV; Pozina IM; Migunov VN; Levina LA
    Zh Mikrobiol Epidemiol Immunobiol; 1994; (6):40-1. PubMed ID: 7879528
    [No Abstract]   [Full Text] [Related]  

  • 3. Affinity-purified human immunoglobulin G that binds a lacto-N-neotetraose-dependent lipooligosaccharide structure is bactericidal for serogroup B Neisseria meningitidis.
    Estabrook MM; Jarvis GA; McLeod Griffiss J
    Infect Immun; 2007 Feb; 75(2):1025-33. PubMed ID: 17101655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis Group B outer membrane protein produces protective antibodies against gram-negative bacteremia.
    Bhattacharjee AK; Opal SM; Taylor R; Naso R; Semenuk M; Zollinger WD; Moran EE; Young L; Hammack C; Sadoff JC; Cross AS
    J Infect Dis; 1996 May; 173(5):1157-63. PubMed ID: 8627067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unique intermolecular bactericidal epitope involving the homosialopolysaccharide capsule on the cell surface of group B Neisseria meningitidis and Escherichia coli K1.
    Jennings HJ; Gamian A; Michon F; Ashton FE
    J Immunol; 1989 May; 142(10):3585-91. PubMed ID: 2469720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neisseria meningitidis antigen NMB0088: sequence variability, protein topology and vaccine potential.
    Sardiñas G; Yero D; Climent Y; Caballero E; Cobas K; Niebla O
    J Med Microbiol; 2009 Feb; 58(Pt 2):196-208. PubMed ID: 19141737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surface antigen analysis of group B Neisseria meningitis outer membrane by monoclonal antibodies: identification of bactericidal antibodies to class 5 protein.
    Danelli MG; Batoreu NM; Lacerda MD; Ferreira CR; Cardoso JD; Peralta JM; Frasch CE
    Curr Microbiol; 1995 Sep; 31(3):146-51. PubMed ID: 7545046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production and characterization of a new monoclonal antibody against Neisseria meningitidis: study of the cross-reactivity with different bacterial genera.
    De Gaspari EN
    Hybridoma; 2000 Dec; 19(6):445-53. PubMed ID: 11152396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear-magnetic-resonance analysis of the capsular antigen of Actinobacillus pleuropneumoniae serotype 9. Its identity with the capsular antigen of Escherichia coli K62 (K2ab), Neisseria meningitidis serogroup H and Pasteurella haemolytica serotype T15.
    Beynon LM; Richards JC; Perry MB
    Eur J Biochem; 1992 Nov; 210(1):119-24. PubMed ID: 1446664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and partial characterization of a novel bipartite protein antigen associated with the outer membrane of Escherichia coli.
    Owen P; Caffrey P; Josefsson LG
    J Bacteriol; 1987 Aug; 169(8):3770-7. PubMed ID: 3301815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping of monoclonal antibodies specific to P64k: a common antigen of several isolates of Neisseria meningitidis.
    Nazábal C; Carmenate T; Cruz S; González S; Silva R; Musacchio A; Delgado M; Chinea G
    Can J Microbiol; 2001 Feb; 47(2):158-64. PubMed ID: 11261496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody studies in mice of outer membrane antigens for use in an improved meningococcal B and C vaccine.
    Milagres LG; Cristina M; Brandileone MC; Sacchi CT; Vieira VS; Zanella RC; Frasch CE
    FEMS Immunol Med Microbiol; 1996 Jan; 13(1):9-17. PubMed ID: 8821393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of the level of antibodies to purified meningococcal antigens].
    Kuznetsova EM; Borisenko IuV; Tsvetkova NV
    Zh Mikrobiol Epidemiol Immunobiol; 1988 Jan; (1):65-8. PubMed ID: 3129887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional activity of anti-Neisserial surface protein A monoclonal antibodies against strains of Neisseria meningitidis serogroup B.
    Moe GR; Zuno-Mitchell P; Lee SS; Lucas AH; Granoff DM
    Infect Immun; 2001 Jun; 69(6):3762-71. PubMed ID: 11349041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development.
    Jennings HJ
    Contrib Microbiol Immunol; 1989; 10():151-65. PubMed ID: 2479499
    [No Abstract]   [Full Text] [Related]  

  • 16. Purity, anticomplementary activity, and viral antibody profile of NIG preparations for intravenous and intramuscular use.
    Scheiermann N; Kuwert EK
    Dev Biol Stand; 1979; 44():165-71. PubMed ID: 544291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neisseria meningitidis serogroup C polysaccharide and serogroup B outer membrane vesicle conjugate as a bivalent meningococcus vaccine candidate.
    Fukasawa LO; Gorla MC; Schenkman RP; Garcia LR; Carneiro SM; Raw I; Tanizaki MM
    Vaccine; 1999 Aug; 17(23-24):2951-8. PubMed ID: 10462229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Escherichia coli K1 colominic acid-specific murine antibodies that are cross-protective against Neisseria meningitidis groups B, C, and Y.
    Park IH; Lin J; Choi JE; Shin JS
    Mol Immunol; 2014 Jun; 59(2):142-53. PubMed ID: 24603121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The molecular parameters of a meningococcal serogroup B protein-polysaccharide vaccine].
    Bobyleva GV; Artiukhova II; Kuvakina VI; Basnak'ian IA
    Zh Mikrobiol Epidemiol Immunobiol; 1996; (5):39-43. PubMed ID: 9082727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Interaction of chaotropically modified immunoglobulins with protein and glicolipid antigens].
    Gordienko AI; Khimich NV
    Ukr Biokhim Zh (1999); 2006; 78(6):78-85. PubMed ID: 17494322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.